新股配售 | 心通醫療-B吸引近57萬人申購,一手中籤率7.5%,公開認購769倍,國配54倍
uSMART盈立智投2月3日消息,心通醫療-B今日公佈發售價及配發結果公告,並將於今日下午進行暗盤交易。
【配售小結】
①火爆:與超級大熱門快手同期招股,心通醫療-B仍吸引了近57萬人申購,公開認購倍數高達769倍。一手中籤率7.5%,申購400手(甲尾)僅穩中1手,乙頭穩2爭3,頂頭槌中30手。
②機構認購熱情高漲:國配認購倍數高達54倍,上一個大熱門醫渡科技的國配倍數爲33.4倍,說明機構認購熱情非常高漲,uSMART多次在配售結果中指出,國配認購倍數越高,首日上漲的概率越大。
③"不是能不能漲的問題,是漲多少的問題":市場上一直拿心通醫療-B與啓明醫療-B進行比較,更指出心通醫療-B有望未來超越啓明醫療-B成行業第一。
心通醫療-B的發行市值是288.67億港元,啓明醫療-B目前市值爲366.92億港元,簡單對標啓明醫療-B,心通醫療-B的空間有27%左右。
若參考中金曾給微創心通的估值介乎310億港元-387億港元,股價約7.4%-34%增長空間。
④甲尾不及乙頭:甲尾打和點約19%,乙頭打和點約9%,頂頭槌打和點約16%,對於正常分配的大票而言,甲尾整體不及乙頭。所以在申購策略上"寧做乙頭不做甲尾"。
uSMART盈立智投暗盤交易時間:2月3日16:15-18:30
【配售簡況】
1、發售價:12.2港元,爲招股價區間(11.1港元-12.2港元)的上限
2、一手市值:12200港元,每手1000股
3、有效申購人數:567,475名(甲組:555,186名,乙組:12,289名)
4、實際中籤人數:63,694名
5、中籤情況:一手中籤率7.5%,申購400手穩中1手,甲尾僅中1手,乙頭穩2爭3,頂頭槌中30手
6、公開認購倍數:769倍(甲組:462倍,乙組:1,077倍)
7、國際發售:認購倍數爲54倍,合共281名承配人
8、優先發售:認購倍數爲29倍
9、回撥情況:最大比例回撥,最終公開佔比50%,國配佔比50%
10、超額配股權:國際發售中已超額分配3084.3萬股股份,有綠鞋
11、基石投資者:高瓴、GIC、清池資本、泰康人壽等16名基石合共鎖定38.6%的發行股份,禁售期6個月
12、uSMART盈立智投暗盤交易時間:2月3日16:15-18:30
注:以上佔比均爲假設超額配售權未獲行使
【中籤詳情】
甲組:
一手中籤率7.5%
申購400手(甲尾)穩中1手
乙組:
申購450手(乙頭)穩2爭3
申購500手穩2爭3
申購600手穩3爭4
申購700手穩3爭4
申購800手穩4爭5
申購900手穩4爭5
申購1000手中5手
申購2000手中9手
……
申購10281手中30手
以下爲中籤分配基準:


【基石投資者】

【禁售承諾】

【股權集中度】

點擊可跳轉閱讀《心通醫療-B發售價及配發結果公告》公告原文件PDF。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.